Has Rabih Fahed, MD received payments from drug or device companies?

Yes. Drug and device makers reported $294,122 in general payments to Rabih Fahed, MD across 538 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Rabih Fahed, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Rabih Fahed, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Rabih Fahed, MD

Hematology & Oncology · Norfolk, NENPI 1043488844

Payments from drug & device makers

$294,122in general payments, 2019–2025

Across 538 payments — averaging $546.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

E.r. Squibb & Sons, L.L.C.$148K
AstraZeneca$49K
Bristol Myers Squibb$21K
Regeneron Healthcare Solutions, Inc.$16K
Seagen Inc.$10K
Incyte Corporation$10K
plus $39K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
E.r. Squibb & Sons, L.L.C.	165	$147,919
AstraZeneca(2 entities)	49	$48,976
Bristol Myers Squibb	23	$21,467
Regeneron Healthcare Solutions, Inc.	17	$16,441
Seagen Inc.	17	$10,228
Incyte Corporation	21	$9,771
Sanofi	8	$6,277
Exelixis Inc.	15	$4,916
Dova Pharmaceuticals	5	$4,291
Athenex Pharmaceutical Division, LLC	5	$4,175
Beigene USA, Inc.	2	$2,450
AbbVie	11	$2,434
Johnson & Johnson	20	$1,981
Daiichi Sankyo Inc.	3	$1,670
Karyopharm Therapeutics Inc.	2	$1,570
Taiho Oncology, Inc.	1	$1,413
Rigel Pharmaceuticals, Inc.	2	$1,216
GSK	4	$880
Pfizer	31	$857
Geron Corporation	1	$780
EMD Serono, Inc.	3	$556
Beigene, Ltd.	1	$525
Genentech USA, Inc.	22	$323
Eisai Inc.	6	$259
Takeda Pharmaceuticals U.S.A., Inc.	13	$257
Novocure GmbH	1	$250
Bayer	4	$240
Astellas Pharma US Inc	8	$225
Sobi, Inc	2	$218
Novartis	10	$175
Pharmaessentia USA Corporation	2	$142
Amgen	8	$129
Pharmacyclics LLC, An Abbvie Company	1	$115
Merck	7	$107
Cardinal Health 110 LLC	1	$100
Lilly USA, LLC	5	$74
Blueprint Medicines Corporation	2	$71
Gilead(2 entities)	5	$70
AVEO Pharmaceuticals, Inc.	3	$55
Servier Pharmaceuticals LLC	2	$46
Acrotech Biopharma Inc.	3	$43
Ipsen Biopharmaceuticals, Inc	2	$42
Myriad Genetic Laboratories, Inc.	2	$42
Puma Biotechnology, Inc.	2	$37
Agios Pharmaceuticals, Inc.	2	$31
Syndax Pharmaceuticals, Inc.	1	$26
Genmab U.S., Inc.	1	$25
Teva Pharmaceuticals USA, Inc.	2	$22
Tempus AI, Inc	1	$18
Clovis Oncology, Inc.	2	$18
Boehringer Ingelheim	1	$17
Immunocore Limited	1	$17
Kyowa Kirin, Inc.	1	$17
Jazz Pharmaceuticals Inc.	1	$16
Tesaro, Inc.	1	$16
Helsinn Therapeutics (U.S.), Inc.	1	$15
Array Biopharma Inc	1	$13
Coherus Oncology, Inc.	1	$13
Sirtex Medical Inc	1	$12
AMAG Pharmaceuticals, Inc.	1	$12

How this compares

$294,122 in reported general payments places this provider in the 65th percentile of 73 hematology & oncology providers in Nebraska.

See all hematology & oncology providers in Nebraska →

Medicare billing

Part B allowed, 2024

$6,774,472

Medicare patients

847

Services billed

258,876

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Norfolk

Luke NordquistOmaha$29.3M
Ralph HaukeOmaha$12.1M
Margaret BlockOmaha$8.3M
Kailash MosalpuriaLincoln$4.2M
Stefano TarantoloOmaha$3.7M
Julie VoseOmaha$3.5M
Debora BrunoHastings$3M
Robert BociekOmaha$3M
Vijaya BhattOmaha$2.2M
Mojtaba AkhtariOmaha$1.9M

See the full list for Nebraska →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →